首页 | 本学科首页   官方微博 | 高级检索  
     


Biomarker‐based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo‐DHF trial
Authors:Susana Ravassa  Tobias Trippel  Doris Bach  Diana Bachran  Arantxa González  Begoña López  Rolf Wachter  Gerd Hasenfuss  Christian Delles  Anna F. Dominiczak  Frank Edelmann
Affiliation:1. University of Navarra, CIMA, Program of Cardiovascular Diseases, IdiSNA, Navarra Institute for Health Research, Pamplona, Spain, CIBERCV, Carlos III Institute of Health, Madrid, Spain;2. Institute for Internal Medicine and Cardiology, Charité Universit?tsmedizin Berlin, Berlin, Germany;3. DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Berlin, Germany;4. Department of Cardiology and Pneumology, University of G?ttingen Medical Centre G?ttingen, G?ttingen, Germany;5. DZHK (German Centre for Cardiovascular Research), Partner Site G?ttingen, G?ttingen, Germany;6. Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK
Abstract:
Keywords:Heart failure with preserved ejection fraction  Spironolactone  Left ventricular diastolic function  Biomarkers of myocardial fibrosis  Carboxy‐terminal propeptide of procollagen type I  Carboxy‐terminal telopeptide of collagen type I  Matrix metalloproteinase‐1
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号